A Study on COPD Phenotypes, Endotypes and Treatable Traits

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous and multisystemic disease with progressive increasing morbidity and mortality. COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes.The recognition of COPD phenotypes and endotypes has significantly impacted the management of the disease. Furthermore, treatable traits (TTs) are recognizable phenotypic or endotypic characteristics that can be assessed and successfully targeted by therapy to improve a clinical outcome in a patient with airway disease. The healthcare system in Hong Kong is different from that of other places. Previous studies in Hong Kong only looked at specific endotypes; an example is the eosinophils cut-off to predict COPD exacerbations and the treatment effect of applying interventions to certain phenotypes, e.g. approaching the exacerbation phenotype with a comprehensive care programme. There is not much information on the overall phenotypes, endotypes, and TTs of COPD patients in Hong Kong. The characteristics of the patients would help to further assess whether the multi-TT approach can improve their outcomes. This study aims to assess 1. the phenotypes, endotypes and treatable traits of COPD patients over time 2. Outcome of patients according to their phenotypes, endotypes and treatable traits over a period of 3 years. 4\) Clustering analyses will also be employed to assess groups of patients with similar characteristics and to assess the change in their outcome over time.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:

• 1\) Patient with COPD with compatible history and lung function assessment according to Global Obstructive Lung Disease (GOLD): Patient has chronic respiratory symptoms (dyspnoea, cough, sputum production and exacerbations due to abnormalities of the airway (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow limitation. Lung function assessment with forced spirometry demonstrated the presence of a post-bronchodilator FEV1/FVC \<70%.14 2) Patient with age ≥40 years

Locations
Other Locations
Hong Kong Special Administrative Region
The Chinese University of Hong Kong
RECRUITING
Hong Kong
Contact Information
Primary
Fanny WS Ko, MD
fannyko@cuhk.edu.hk
852 35033133
Backup
David SC Hui, MD
dschui@cuhk.edu.hk
852 35053133
Time Frame
Start Date: 2025-05-02
Estimated Completion Date: 2030-04-24
Participants
Target number of participants: 460
Treatments
COPD patients
Prospective COPD subjects will be recruited from the hospital
Sponsors
Leads: Chinese University of Hong Kong

This content was sourced from clinicaltrials.gov